阿托伐他汀联合曲美他嗪治疗冠状动脉粥样硬化性心脏病的效果

Effect of atorvastatin combined with trimetazidine on patients with coronary heart disease

目的研究阿托伐他汀联合曲美他嗪对冠状动脉粥样硬化性心脏病(简称冠心病)患者的治疗效果。方法选取山西省人民医院2015年3月至2017年3月收治的冠心病患者180例作为研究对象,采用随机数字表法分为观察组和对照组,每组90例。对照组予以曲美他嗪治疗,观察组则予以阿托伐他汀联合曲美他嗪治疗。比较两组临床疗效,治疗前后血脂水平、血浆N端脑钠肽前体(NT-proBNP)、高敏C反应蛋白(hs-CRP)、血浆纤维蛋白原(Fib)含量、左心室舒张末期内径(LVEDD)、左心室射血分数(LVEF)、后壁厚度(LVPWd)。结果观察组治疗总有效率为84.44%(76/90),高于对照组[68.89%(62/90)];观察组总胆固醇(TC)、三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)水平均低于对照组。两组NT-proBNP、hs-CRP、Fib含量均降低,但观察组均低于对照组;两组心功能均有所改善,但观察组LVEDD、LVPWd低于对照组,LVEF高于对照组,组间比较差异均有统计学意义(P均<0.05)。结论阿托伐他汀联合曲美他嗪治疗冠心病疗效显著,能增强患者心脏射血能力,有效改善患者血脂水平,降低NT-proBNP、Fib含量,值得临床广泛推广应用。

ObjectiveTo investigate the effect of atorvastatin combined with trimetazidine on blood biochemical indexes and cardiac function in patients with coronary heart disease (CHD).MethodsA total of 180 CHD patients admitted to Shanxi People's Hospital from March 2015 to March 2017 were selected as the study subjects and they were divided into observation group and control group by random number table method, with 90 cases in each group. The control group was treated with trimetazidine and the observation group was treated with atorvastatin combined with trimetazidine. The clinical efficacy of the two groups was compared, including serum lipid level before and after treatment, plasma N-terminal B-type natriuretic peptide(NT-proBNP), high-sensitivity c-reactive protein (hs-CRP) and plasma fibrinogen (Fib), left ventricular distal diastolic internal diameter (LVEDD), left ventricular ejection fraction (LVEF), posterior wall thickness (LVPWd).ResultsThe total therapeutic efficiency of the observation group was 84.44% (76/90), which was significantly higher than that of the control group [68.89% (62/90)]. The levels of total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) of the observation group were significantly lower than those of the control group (P<0.05). The contents of NT-proBNP, hs-CRP and Fib in the two groups were significantly decreased, but the levels of the observation group was significantly lower than those of the control group (P<0.05). The heart function of the two groups was improved, but LVEDD and LVPWd of the observation group were significantly lower than that of the control group, and LVEF of the observation group was higher than that of the control group, and the differences between the two groups were significant (P all<0.05).ConclusionsAtorvastatin combined with trimetazidine has significant effect on coronary heart disease, which can enhance the ability of cardiac ejection, effectively improve the blood lipids of patients, and reduce the content of NT-proBNP and Fib, so it should be widely used in clinical practice.